AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study NCT02333071 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Bremelanotide
Description: A melanocortin agonist and synthetic peptide analog of the naturally occurring hormone alpha-MSH (melanocyte-stimulating hormone)
Study NCT02333071 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Bremelanotide
Description: A melanocortin agonist and synthetic peptide analog of the naturally occurring hormone alpha-MSH (melanocyte-stimulating hormone)
Study NCT02333071 — intervention group
Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo
Study NCT01963442 — intervention group
Intervention type: RADIATION
Group type: ACTIVE_COMPARATOR
Intervention: Chest X-ray
Description: at Day 0, Day 30 and relapse
Study NCT01963442 — intervention group
Intervention type: RADIATION
Group type: PLACEBO_COMPARATOR
Intervention: Chest X-ray
Description: at Day 0, Day 30 and relapse
Study NCT01963442 — intervention group
Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: blood sampling /Cell Counts/ C reactive protein (CRP)/Biochemistry
Study NCT01963442 — intervention group
Intervention type: BIOLOGICAL
Group type: PLACEBO_COMPARATOR
Intervention: blood sampling /Cell Counts/ C reactive protein (CRP)/Biochemistry
Study NCT01963442 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Augmentin
Description: 2 tablets 3 times a day for 5 days from Day 3
Study NCT01963442 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo (for Augmentin)
Description: 2 tablets 3 times a day for 5 days from Day 3
Study NCT02756767 — intervention group
Intervention type: OTHER
Intervention: Survey
Study NCT04885023 — intervention group
Intervention type: OTHER
Group type: OTHER
Intervention: Hippotherapy
Description: The hippotherapy program for 10 weeks
Study NCT04885023 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Hippotherapy
Description: The hippotherapy program for 10 weeks
Study NCT00781976 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: AZD7295
Description: 700mg per day maximum
Study NCT00781976 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: matched placebo
Study NCT02115958 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: cancer stem cell vaccine
Study NCT02115958 — intervention group
Intervention type: BIOLOGICAL
Group type: PLACEBO_COMPARATOR
Intervention: cancer stem cell vaccine
Study NCT00983073 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Tapentadol
Description: Tapentadol Prolonged Release (PR) Titration and Optimal Dose Period: Starting at 50 mg Tapentadol PR twice daily, adjusting at 50 mg PR steps (upwards or downwards) as necessary to achieve a balance between pain relief and a satisfactory level of tolerability. Participants were not permitted to exceed 500 mg of Tapentadol per day.~Maintenance Period: Participants continuing on the dose established in the previous period.
Study NCT01029223 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ivabradine
Study NCT01029223 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: metoprolol
Study NCT01029223 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: placebo
Study NCT03784339 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Physiotherapy + education
Description: Participants will take part in a 30 minute education session surrounding fear of movement and catastrophizing thoughts. They will then receive standard care, which will involve strength exercises and taping if needed.
Study NCT03784339 — intervention group
Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Physiotherapy
Description: Standard physiotherapy care
Study NCT03784339 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Physiotherapy
Description: Standard physiotherapy care
Study NCT01373528 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Budesonide irrigation
Description: A budesonide (1 mg) in saline (240 mL) irrigation solution is applied to the sinonasal cavities twice daily. 120 mL of the solution is applied via irrigation in the AM, and 120 mL again in the PM.
Study NCT02450318 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Slow-paced walking
Description: Subjects will walk on a treadmill at a slow pace for 47 minutes
Study NCT03166761 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Dexamethasone
Description: Dexamethasone injection into the sacroiliac joint
Study NCT03166761 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Triamcinolone Acetonide
Description: Triamcinolone injection into the sacroiliac joint
Study NCT03217110 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Repetitive Transcranial Magnetic Stimulation (rTMS)
Description: Subjects with neuropsychiatric diagnoses and matched-controls will be receive theta frequency stimulation of the cerebellum. We will target the cerebellar vermis.
Study NCT03217110 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Repetitive Transcranial Magnetic Stimulation (rTMS)
Description: Subjects with neuropsychiatric diagnoses and matched-controls will be receive theta frequency stimulation of the cerebellum. We will target the cerebellar vermis.
Study NCT03217110 — intervention group
Intervention type: DEVICE
Group type: SHAM_COMPARATOR
Intervention: Sham Repetitive Transcranial Magnetic Stimulation (rTMS)
Description: Subjects with neuropsychiatric diagnoses and matched-controls will be receive sham stimulation of the cerebellum. We will target the cerebellar vermis.
Study NCT01525732 — intervention group
Intervention type: PROCEDURE
Group type: OTHER
Intervention: Per Oral Endoscopic Myotomy
Study NCT01767740 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: ULTRABRAID PLUS SUTURE
Description: Rotator Cuff Repair with ULTRABRAID PLUS SUTURE
Study NCT01767740 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: ULTRABRAID SUTURE
Description: Rotator Cuff Repair with ULTRABRAID SUTURE
Study NCT03133975 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Vitamin D3 (Treatment)
Description: Single high dose vitamin D3 in treatment of dyslipedemia
Study NCT03133975 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Mixed diet of carbohydrate and protein (Control)
Description: Mixed diet of carbohydrate and protein
Study NCT04440566 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: blood sample
Description: 30 ml whole blood for Peripheral blood mononuclear cell (PBMC) and monocytes isolation
Study NCT03459430 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Core stability training
Description: Effect of different core stability programs using diverse training intensities
Study NCT02243943 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Sugammadex
Study NCT02243943 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Neostigmine
Study NCT00624299 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Botox
Description: Botox injection (100 ius) per muscle
Study NCT00624299 — intervention group
Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Saline
Description: Saline injection
Study NCT02495272 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Oxytocin
Description: Oxytocin 10IU Administered intramuscularly.
Study NCT02495272 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Oxytocin
Description: Oxytocin 10IU Administered intramuscularly.
Study NCT03381495 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ropivacaine Hydrochloride, Sufentanil
Description: In this research one group will receive epidural analgesia(Ropivacaine Hydrochloride, Sufentanil), data will be collected and analyzed between this group and non-epidural analgesia group.
Study NCT03350646 — intervention group
Intervention type: OTHER
Group type: OTHER
Intervention: Volume of medium during embryo transfer
Study NCT02855372 — intervention group
Intervention type: PROCEDURE
Intervention: Lung transplantation
Study NCT00730860 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: radiofrequency ablation associated with TACE
Description: treatment of hepatocellular carcinoma by radiofrequency ablation associated with postoperative transhepatic arterial chemoembolization
Study NCT00730860 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: radiofrequency ablation only
Description: treatment of hepatocellular carcinoma by radiofrequency ablation only
Study NCT01379768 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Lotrafilcon A contact lens
Description: Commercially marketed, silicone hydrogel, single-vision contact lens FDA-approved for daily and extended (overnight) wear for up to 30 nights.
Study NCT01379768 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Lotrafilcon B contact lens
Description: Commercially marketed, silicone hydrogel, single-vision contact lens FDA-approved for daily or extended (overnight) wear up to 6 nights.
Study NCT01379768 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Clear Care Cleaning and Disinfection Solution
Description: Hydrogen peroxide-based contact lens care system for nightly cleaning and disinfection of study lenses
Study NCT03819712 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Collection of blood samples
Description: 23 mL of blood will be collected during the inclusion visit
Study NCT01963442 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Beta-Lactams
Description: administered from Day 0 to Day 3
Study NCT01963442 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Beta-Lactams
Description: administered from Day 0 to Day 3
Study NCT02149576 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Low Dose Computed Tomography Imaging
Study NCT02149576 — intervention group
Intervention type: PROCEDURE
Group type: OTHER
Intervention: Chest Radiograph Imaging
Study NCT01381614 — intervention group
Intervention type: DRUG
Intervention: Targeted agents indicated in management of advanced/metastatic RCC (sunitinib, sorafenib, bevacizumab, and pazopanib)
Description: Metastatic RCC patients on either sunitinib or sorafenib or bevacizumab or pazopanib (identified based on claims) will be evaluated for presence or absence of common severe adverse events. These common severe adverse events will be identified from agent's product labels.
Study NCT01514864 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Dasatinib
Description: Tablet, oral, 140 mg, once daily until unacceptable toxicity or disease progression
Study NCT04361916 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: home care monitoring
Description: home care active monitoring of patients with suspected of confirmed COVID-19
Study NCT03344913 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Walking
Description: walking 30 minutes per day, three days/week for 6 weeks with a member of study team.
Study NCT03377283 — intervention group
Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: organ perfusion with rabbit anti-thymocyte globulin (rATG)
Study NCT03377283 — intervention group
Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: organ perfusion with saline
Study NCT01383616 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Kyphon® Balloon Kyphoplasty (Kyphon Inc; Sunnydale, CA)
Description: A Jamshidi Crown Bone Biopsy Needle (Cardinal Health; Dublin, OH) was then introduced through the incision into the pedicle, and advanced through the pedicle into the center of the vertebral body using a mallet at a 30 to 45 degree angle relative to the AP axis. A guidewire was then placed through the Jamshidi needle, and the needle removed. A series of dilating cannulae were then advanced over the guidewire until a working cannula was in place. A 15 millimeter (mm) or 20 mm bone tamp (Kyphon Inc; Sunnydale, CA) was then introduced into the vertebral body via the cannula and inflated until the balloon was in contact with the subchondral plate, lateral vertebral body wall, or anterior cortex of the vertebral body. The balloon was then deflated and removed. Subsequently, cement was injected into the cavity and allowed to harden.
Study NCT02841085 — intervention group
Intervention type: GENETIC
Intervention: Genetic sample
Description: Blood sample or saliva collection
Study NCT03819712 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Collection of fecal samples
Description: Fecal sample self-collected after the inclusion visit
Study NCT03819712 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Collection of urine samples
Description: 10 mL of urine will be collected during the inclusion visit
Study NCT04747847 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Atorvastatin and anakinra
Description: Anakinra up to 8 mg/kg/day and atorvastatin at 0.75 mg/kg/day in children with acute KD at least 1 year old with CAA
Study NCT03340818 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Bone Marrow Concentrate
Description: Bone marrow concentrate is bone marrow harvested from the iliac crest and minimally processed in a centrifuge. It is then injected into the suspected painful disc (s) using fluoroscopic guidance
Study NCT03340818 — intervention group
Intervention type: OTHER
Group type: SHAM_COMPARATOR
Intervention: Placebo
Description: Injection of normal saline dorsal to the transverse process after sham bone marrow aspiration
Study NCT02160561 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Intervention Arm
Description: Placing patients who are in critical illness with acute respiratory failure and are mechanically ventilated in an upright reverse trendelenburg position
Study NCT00614536 — intervention group
Intervention type: DRUG
Intervention: Rabeprazole Sodium
Description: 10mg - 20mg tablet once or twice daily for 12weeks
Study NCT03819712 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Collection of vaginal swaps
Description: Sample of vaginal microbiota collected during the inclusion visit
Study NCT03477539 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Autologous Hematopoietic Stem Cell Transplantation
Description: Undergo ASCT
Study NCT02222844 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Preoperative MRI scan
Description: Standard preoperative CT of abdomen, chest and pelvis plus interventional preoperative MRI scan.
Study NCT03477539 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Daratumumab
Description: Given IV
Study NCT03477539 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Lenalidomide
Description: Given PO
Study NCT02754427 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Prospective Surveillance Group
Description: Participants received a pre-surgery arm assessment for shoulder mobility, upper body muscle strength, upper body function, and arm volume. Same assessment was repeated at 12 months post-surgery. After surgery, participants randomized to the surveillance group underwent the same arm assessment at 3, 6, and 9 months post-surgery. If arm morbidity was detected at any of those time points, then the participant was referred to individual physiotherapy treatment until the issue was resolved.
Study NCT02754427 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Education Group
Description: Participants received a pre-surgery arm assessment for shoulder mobility, upper body muscle strength, upper body function, and arm volume. Same assessment was repeated at 12 months post-surgery. After surgery, participants randomized to the education group were asked to attend three patient education sessions on nutrition, stress management, and fatigue management of approximately 1 hour, delivered at 3, 6, and 9 months by study staff.
Study NCT02168257 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: RAM Cannula
Study NCT02168257 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Binasal Prong CPAP
Study NCT01256489 — intervention group
Intervention type: DRUG
Group type: OTHER
Intervention: Infliximab
Description: The drug will be administered intravenously every month for 110 weeks (duration of the study). The initial dose of infliximab will be 5mg/kg of body weight. The dose may be adjusted up to a maximal dosing of 10mg/kg depending upon disease activity, as judged by the investigators.
Study NCT01975142 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Trastuzumab - Emtansine
Study NCT02928653 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Beverage
Description: Participants will receive 1.25 - 1.75 L of sweetened beverage a day for 12 weeks
Study NCT02928653 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: Beverage
Description: Participants will receive 1.25 - 1.75 L of sweetened beverage a day for 12 weeks
Study NCT01666158 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Exercise
Description: The exercise component will consist of 20 min of general exercise training, 3 days per week, alternating between aerobic and resistance training. The exercise program will be individualized based upon the baseline fitness test (according to the American College of Sport Medicine, ACMS, standard) and will include: a 5 min warm-up, either 25 min of aerobic exercise (starting at 30- 40 of heart rate reserve, HRR), or 25 min of resistance training (5 exercises targeting major muscle groups performed at an intensity of 8-12 repetition maximum), and a 5 min cool-down.
Study NCT04344028 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: True Cognitive Training Program
Description: The training program is a personal device-based adaptive version of a visual N-back task.
Study NCT04344028 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: True Cognitive Training Program
Description: The training program is a personal device-based adaptive version of a visual N-back task.
Study NCT04344028 — intervention group
Intervention type: BEHAVIORAL
Group type: SHAM_COMPARATOR
Intervention: Control Cognitive Training Program
Description: The training program is a personal device-based adaptive version of a knowledge task (control).
Study NCT04344028 — intervention group
Intervention type: BEHAVIORAL
Group type: PLACEBO_COMPARATOR
Intervention: Control Cognitive Training Program
Description: The training program is a personal device-based adaptive version of a knowledge task (control).
Study NCT02396498 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: HIPEC
Description: Using cisplatin in HIPEC plus oral S-1
Study NCT03743987 — intervention group
Intervention type: PROCEDURE
Group type: SHAM_COMPARATOR
Intervention: control group
Description: a procedure used to prevent or resolves apical periodontitis.
Study NCT03743987 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: MTA group
Description: a procedure used to prevent or resolves apical periodontitis.
Study NCT03743987 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: PRF group
Description: a procedure that is used for wound healing
Study NCT03743987 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: MTA + PRF group
Description: a procedure used to prevent or resolves apical periodontitis in combination with a procedure that is used for wound healing.
Study NCT01910740 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Enhanced Physical Activity
Description: Individually tailored programs focused on increasing the amount of time participants spend performing mobility activities, particularly standing and walking in the late afternoons and evenings and on weekends. These participants will be provided with one or two extra sessions on weekdays and two extra sessions on weekend days for the duration of their rehabilitation stay.
Study NCT04344028 — intervention group
Intervention type: BEHAVIORAL
Group type: PLACEBO_COMPARATOR
Intervention: Positive Expectation Induction
Description: The message given to the participants emphasizes that the given training results in a positive change in cognitive abilities.
Study NCT04344028 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Positive Expectation Induction
Description: The message given to the participants emphasizes that the given training results in a positive change in cognitive abilities.
Study NCT04344028 — intervention group
Intervention type: BEHAVIORAL
Group type: SHAM_COMPARATOR
Intervention: Negative Expectation Induction
Description: The message given to the participants emphasizes that the given training results in a negative change in cognitive abilities.
Study NCT04344028 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Negative Expectation Induction
Description: The message given to the participants emphasizes that the given training results in a negative change in cognitive abilities.
Study NCT03074058 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Fosrenol ODT (Lanthanum Carbonate, BAY77-1931)
Description: Fosrenol orally disintegrating tablet, ODT (Lanthanum Carbonate, BAY77-1931) 500 mg, TID
Study NCT03074058 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Fosrenol chewable Tablet (Lanthanum Carbonate, BAY77-1931)
Description: Fosrenol chewable Tablet (Lanthanum Carbonate, BAY77-1931) 500mg, TID
Study NCT00904358 — intervention group
Intervention type: DIAGNOSTIC_TEST
Intervention: cross sectional area
Study NCT01910740 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Usual Care
Description: Therapy provided by a multidisciplinary team which includes physiotherapy and occupational therapy on weekdays with other allied health input (eg speech pathology, social work) as indicated. Medical and nursing care is also provided seven days a week.